The DOI matches its Crossref record; 191 of the 191 references it cites were found in a registry or an index.
Towards a muscarinic hypothesis of schizophrenia
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Effectiveness of Antipsychotic Drugs in Patients with Chronic Schizophrenia
Lieberman, J. A., Stroup, T. S., McEvoy, J. P., Swartz, M. S., Rosenheck, R. A., Perkins, D. O., Keefe, R. S. E., Davis, S. M., Davis, C. E., Lebowitz, B. D., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa051688 · Cited by 5,892
The cholinergic hypothesis of geriatric memory dysfunction
Bartus, R. T., Dean, R. L., Beer, B., & Lippa, A. S. (1982) · Science · doi:10.1126/science.7046051 · Cited by 5,545
Clozapine for the Treatment-Resistant Schizophrenic: A Double-blind Comparison With Chlorpromazine
Kane, J. (1988) · Archives of General Psychiatry · doi:10.1001/archpsyc.1988.01800330013001 · Cited by 4,156
What are the functional consequences of neurocognitive deficits in schizophrenia?
(1996) · American Journal of Psychiatry · doi:10.1176/ajp.153.3.321 · Cited by 3,516
Dopamine Receptor Binding Predicts Clinical and Pharmacological Potencies of Antischizophrenic Drugs
Creese, I., Burt, D. R., & Snyder, S. H. (1976) · Science · doi:10.1126/science.3854 · Cited by 2,220
Mesulam, M. ‐., Mufson, E. J., Levey, A. I., & Wainer, B. H. (1983) · Journal of Comparative Neurology · doi:10.1002/cne.902140206 · Cited by 1,962
The Biochemical Basis of Neuropharmacology.
(1974) · Annals of Internal Medicine · doi:10.7326/0003-4819-81-4-575_2 · Cited by 1,878
Glutamate receptor dysfunction and schizophrenia
Olney, J. W. (1995) · Archives of General Psychiatry · doi:10.1001/archpsyc.1995.03950240016004 · Cited by 1,685
Antipsychotic drug doses and neuroleptic/dopamine receptors
SEEMAN, P., LEE, T., CHAU-WONG, M., & WONG, K. (1976) · Nature · doi:10.1038/261717a0 · Cited by 1,622
Identification of a Family of Muscarinic Acetylcholine Receptor Genes
Bonner, T. I., Buckley, N. J., Young, A. C., & Brann, M. R. (1987) · Science · doi:10.1126/science.3037705 · Cited by 1,427
Hulme, E. C., Birdsall, N. J. M., & Buckley, N. J. (1990) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pa.30.040190.003221 · Cited by 1,338
Laruelle, M., Abi-Dargham, A., van Dyck, C. H., Gil, R., D'Souza, C. D., Erdos, J., McCance, E., Rosenblatt, W., Fingado, C., Zoghbi, S. S., et al. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.17.9235 · Cited by 1,291
Breier, A., Su, T.-P., Saunders, R., Carson, R. E., Kolachana, B. S., de Bartolomeis, A., Weinberger, D. R., Weisenfeld, N., Malhotra, A. K., Eckelman, W. C., et al. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.6.2569 · Cited by 1,154
GABAergic Interneurons Implications for Understanding Schizophrenia and Bipolar Disorder
Benes, F. (2001) · Neuropsychopharmacology · doi:10.1016/s0893-133x(01)00225-1 · Cited by 1,082
Radioreceptor Binding Profile of the Atypical Antipsychotic Olanzapine
Bymaster, F. P., Calligaro, D. O., Falcone, J. F., Marsh, R. D., Moore, N. A., Tye, N. C., Seeman, P., & Wong, D. T. (1996) · Neuropsychopharmacology · doi:10.1016/0893-133x(94)00129-n · Cited by 1,062
Self-citationIncreased baseline occupancy of D 2 receptors by dopamine in schizophrenia
Abi-Dargham, A., Rodenhiser, J., Printz, D., Zea-Ponce, Y., Gil, R., Kegeles, L. S., Weiss, R., Cooper, T. B., Mann, J. J., Van Heertum, R. L., et al. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.97.14.8104 · Cited by 1,020
The current status of the dopamine hypothesis of schizophrenia
CARLSSON, A. (1988) · Neuropsychopharmacology · doi:10.1016/0893-133x(88)90012-7 · Cited by 958
Levey, A., Kitt, C., Simonds, W., Price, D., & Brann, M. (1991) · The Journal of Neuroscience · doi:10.1523/jneurosci.11-10-03218.1991 · Cited by 918
Kubo, T., Fukuda, K., Mikami, A., Maeda, A., Takahashi, H., Mishina, M., Haga, T., Haga, K., Ichiyama, A., Kangawa, K., et al. (1986) · Nature · doi:10.1038/323411a0 · Cited by 906
Increased Striatal Dopamine Transmission in Schizophrenia: Confirmation in a Second Cohort
Abi-Dargham, A., Gil, R., Krystal, J., Baldwin, R. M., Seibyl, J. P., Bowers, M., van Dyck, C. H., Charney, D. S., Innis, R. B., & Laruelle, M. (1998) · American Journal of Psychiatry · doi:10.1176/ajp.155.6.761 · Cited by 803
Cloning and expression of the human and rat m5 muscarinic acetylcholine receptor genes
Bonner, T. I., Young, A. C., Bran, M. R., & Buckley, N. J. (1988) · Neuron · doi:10.1016/0896-6273(88)90190-0 · Cited by 783
Acetylcholine in mind: a neurotransmitter correlate of consciousness?
Perry, E., Walker, M., Grace, J., & Perry, R. (1999) · Trends in Neurosciences · doi:10.1016/s0166-2236(98)01361-7 · Cited by 763
The Cholinergic Synapse and the Site of Memory
Deutsch, J. A. (1972) · Advances in Behavioral Biology · doi:10.1007/978-1-4684-3060-8_11 · Cited by 739
Assessing the Validity of an Animal Model of Deficient Sensorimotor Gating in Schizophrenic Patients
Swerdlow, N. R. (1994) · Archives of General Psychiatry · doi:10.1001/archpsyc.1994.03950020063007 · Cited by 703
Bodick, N. C., Offen, W. W., Levey, A. I., Cutler, N. R., Gauthier, S. G., Satlin, A., Shannon, H. E., Tollefson, G. D., Rasmussen, K., Bymaster, F. P., et al. (1997) · Archives of Neurology · doi:10.1001/archneur.1997.00550160091022 · Cited by 692
Self-citationThe Cholinergic Synapse and the Site of Memory
Deutsch, J. A. (1971) · Science · doi:10.1126/science.174.4011.788 · Cited by 661
THE ACTION OF CERTAIN ESTERS AND ETHERS OF CHOLINE, AND THEIR RELATION TO MUSCARINE
DALE, H. H. (1914) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)08268-0 · Cited by 651
Antagonist binding properties of five cloned muscarinic receptors expressed in CHO-K1 cells.
Buckley, N. J., Bonner, T. I., Buckley, C. M., & Brann, M. R. (1989) · Molecular Pharmacology · doi:10.1016/s0026-895x(25)11261-3 · Cited by 635
Studies of Cognitive Change in Patients With Schizophrenia Following Novel Antipsychotic Treatment
Harvey, P. D., & Keefe, R. S. E. (2001) · American Journal of Psychiatry · doi:10.1176/appi.ajp.158.2.176 · Cited by 620
Meltzer, H. Y. (1989) · Psychopharmacology · doi:10.1007/bf00442554 · Cited by 602
Targeting the dopamine D1 receptor in schizophrenia: insights for cognitive dysfunction
Goldman-Rakic, P., Castner, S., Svensson, T., Siever, L., & Williams, G. (2004) · Psychopharmacology · doi:10.1007/s00213-004-1793-y · Cited by 544
Selective cognitive dysfunction in acetylcholine M1 muscarinic receptor mutant mice
Anagnostaras, S. G., Murphy, G. G., Hamilton, S. E., Mitchell, S. L., Rahnama, N. P., Nathanson, N. M., & Silva, A. J. (2003) · Nature Neuroscience · doi:10.1038/nn992 · Cited by 544
Cognitive Impairments in Patients With Schizophrenia Displaying Preserved and Compromised Intellect
Weickert, T. W., Goldberg, T. E., Gold, J. M., Bigelow, L. B., Egan, M. F., & Weinberger, D. R. (2000) · Archives of General Psychiatry · doi:10.1001/archpsyc.57.9.907 · Cited by 538
Proof-of-Concept Trial of an α7 Nicotinic Agonist in Schizophrenia
Olincy, A., Harris, J. G., Johnson, L. L., Pender, V., Kongs, S., Allensworth, D., Ellis, J., Zerbe, G. O., Leonard, S., Stevens, K. E., et al. (2006) · Archives of General Psychiatry · doi:10.1001/archpsyc.63.6.630 · Cited by 527
Kellendonk, C., Simpson, E. H., Polan, H. J., Malleret, G., Vronskaya, S., Winiger, V., Moore, H., & Kandel, E. R. (2006) · Neuron · doi:10.1016/j.neuron.2006.01.023 · Cited by 520
Muscarinic acetylcholine receptors: signal transduction through multiple effectors
Felder, C. C. (1995) · The FASEB Journal · doi:10.1096/fasebj.9.8.7768353 · Cited by 505
Expression of muscarinic acetylcholine and dopamine receptor mRNAs in rat basal ganglia.
Weiner, D. M., Levey, A. I., & Brann, M. R. (1990) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.87.18.7050 · Cited by 480
Localization of a family of muscarinic receptor mRNAs in rat brain
Buckley, N., Bonner, T., & Brann, M. (1988) · The Journal of Neuroscience · doi:10.1523/jneurosci.08-12-04646.1988 · Cited by 476
Modulatory functions of neurotransmitters in the striatum: ACh/dopamine/NMDA interactions
Di Chiara, G., Morelli, M., & Consolo, S. (1994) · Trends in Neurosciences · doi:10.1016/0166-2236(94)90005-1 · Cited by 467
Cummings, J. L. (2002) · JAMA · doi:10.1001/jama.287.18.2335 · Cited by 439
Abi-Dargham, A., Krystal, J. H., Anjilvel, S., Scanley, B. E., Zoghbi, S., Baldwin, R. M., Rajeevan, N., Ellis, S., Petrakis, I. L., Seibyl, J. P., et al. (1998) · American Journal of Psychiatry · doi:10.1176/ajp.155.11.1550 · Cited by 405
Choline transporters, cholinergic transmission and cognition
Sarter, M., & Parikh, V. (2005) · Nature Reviews Neuroscience · doi:10.1038/nrn1588 · Cited by 400
Hagger, C., Buckley, P., Kenny, J. T., Friedman, L., Ubogy, D., & Meltzer, H. Y. (1993) · Biological Psychiatry · doi:10.1016/0006-3223(93)90043-d · Cited by 393
Kapur, S., & Remington, G. (2001) · Biological Psychiatry · doi:10.1016/s0006-3223(01)01251-3 · Cited by 390
Hamilton, S. E., Loose, M. D., Qi, M., Levey, A. I., Hille, B., McKnight, G. S., Idzerda, R. L., & Nathanson, N. M. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.24.13311 · Cited by 366
Nicotinic receptors in the brain. Links between molecular biology and behavior
Picciotto, M. (2000) · Neuropsychopharmacology · doi:10.1016/s0893-133x(99)00146-3 · Cited by 354
Tandon, R. (1989) · Archives of General Psychiatry · doi:10.1001/archpsyc.1989.01810080075010 · Cited by 351
Self-citationPronounced pharmacologic deficits in M2 muscarinic acetylcholine receptor knockout mice
Gomeza, J., Shannon, H., Kostenis, E., Felder, C., Zhang, L., Brodkin, J., Grinberg, A., Sheng, H., & Wess, J. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.4.1692 · Cited by 348
Molecular aspects of glutamate dysregulation: implications for schizophrenia and its treatment
Konradi, C., & Heckers, S. (2003) · Pharmacology & Therapeutics · doi:10.1016/s0163-7258(02)00328-5 · Cited by 336
The Biochemical Basis of Neuropharmacology
(1997) · Biomedicine & Pharmacotherapy · doi:10.1016/s0753-3322(97)89442-5 · Cited by 328
Gomeza, J., Zhang, L., Kostenis, E., Felder, C., Bymaster, F., Brodkin, J., Shannon, H., Xia, B., Deng, C.-X., & Wess, J. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.18.10483 · Cited by 322
Self-citationZhang, W., Basile, A. S., Gomeza, J., Volpicelli, L. A., Levey, A. I., & Wess, J. (2002) · The Journal of Neuroscience · doi:10.1523/jneurosci.22-05-01709.2002 · Cited by 315
Raiteri, M., Leardi, R., & Marchi, M. (1984) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)21528-2 · Cited by 314
(1993) · American Journal of Psychiatry · doi:10.1176/ajp.150.9.1355 · Cited by 307
Sur, C., Mallorga, P. J., Wittmann, M., Jacobson, M. A., Pascarella, D., Williams, J. B., Brandish, P. E., Pettibone, D. J., Scolnick, E. M., & Conn, P. J. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1835612100 · Cited by 294
Receptor-effector coupling by G proteins: implications for normal and abnormal signal transduction
Spiegel, A. M. (1992) · Endocrine Reviews · doi:10.1210/er.13.3.536 · Cited by 289
Receptor-Effector Coupling by G Proteins: Implications for Normal and Abnormal Signal Transduction
SPIEGEL, A. M., SHENKER, A., & WEINSTEIN, L. S. (1992) · Endocrine Reviews · doi:10.1210/edrv-13-3-536 · Cited by 283
Association of Anticholinergic Load With Impairment of Complex Attention and Memory in Schizophrenia
Minzenberg, M. J., Poole, J. H., Benton, C., & Vinogradov, S. (2004) · American Journal of Psychiatry · doi:10.1176/appi.ajp.161.1.116 · Cited by 283
Perry, E. K., & Perry, R. H. (1995) · Brain and Cognition · doi:10.1006/brcg.1995.1255 · Cited by 278
Vilaró, M. T., Palacios, J., & Mengod, G. (1990) · Neuroscience Letters · doi:10.1016/0304-3940(90)90064-g · Cited by 268
Gerber, D. J., Sotnikova, T. D., Gainetdinov, R. R., Huang, S. Y., Caron, M. G., & Tonegawa, S. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.261583798 · Cited by 264
Mrzljak, L., Levey, A. I., & Goldman-Rakic, P. S. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.11.5194 · Cited by 256
Weiner, D. M., Meltzer, H. Y., Veinbergs, I., Donohue, E. M., Spalding, T. A., Smith, T. T., Mohell, N., Harvey, S. C., Lameh, J., Nash, N., et al. (2004) · Psychopharmacology · doi:10.1007/s00213-004-1940-5 · Cited by 253
Ichikawa, J. (2002) · Neuropsychopharmacology · doi:10.1016/s0893-133x(01)00312-8 · Cited by 248
Neurotransmitter Receptors in Frontal Cortex of Schizophrenics
Bennett, J. P. (1979) · Archives of General Psychiatry · doi:10.1001/archpsyc.1979.01780090013001 · Cited by 248
Differential Regulation of Molecular Subtypes of Muscarinic Receptors in Alzheimer's Disease
Flynn, D. D., Ferrari‐DiLeo, G., Mash, D. C., & Levey, A. I. (1995) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.1995.64041888.x · Cited by 234
Crook, J. M., Tomaskovic-Crook, E., Copolov, D. L., & Dean, B. (2000) · Biological Psychiatry · doi:10.1016/s0006-3223(00)00918-5 · Cited by 228
Self-citationCrook, J. M., Tomaskovic-Crook, E., Copolov, D. L., & Dean, B. (2001) · American Journal of Psychiatry · doi:10.1176/appi.ajp.158.6.918 · Cited by 227
Self-citationZhang, W., Yamada, M., Gomeza, J., Basile, A. S., & Wess, J. (2002) · The Journal of Neuroscience · doi:10.1523/jneurosci.22-15-06347.2002 · Cited by 224
Yasuda, R. P., Ciesla, W., Flores, L. R., Wall, S. J., Li, M., Satkus, S. A., Weisstein, J. S., Spagnola, B. V., & Wolfe, B. B. (1993) · Molecular Pharmacology · doi:10.1016/s0026-895x(25)13594-3 · Cited by 217
Blaha, C., Allen, L., Das, S., Inglis, W., Latimer, M., Vincent, Sr., & Winn, P. (1996) · The Journal of Neuroscience · doi:10.1523/jneurosci.16-02-00714.1996 · Cited by 216
In Vivo Determination of Muscarinic Acetylcholine Receptor Availability in Schizophrenia
Raedler, T. J., Knable, M. B., Jones, D. W., Urbina, R. A., Gorey, J. G., Lee, K. S., Egan, M. F., Coppola, R., & Weinberger, D. R. (2003) · American Journal of Psychiatry · doi:10.1176/appi.ajp.160.1.118 · Cited by 216
Self-citationFreedman, R., Adams, C. E., & Leonard, S. (2000) · Journal of Chemical Neuroanatomy · doi:10.1016/s0891-0618(00)00109-5 · Cited by 214
The cholinergic innervation of the human cerebral cortex.
Mesulam, M.-M. (2004) · Progress in Brain Research · doi:10.1016/s0079-6123(03)45004-8 · Cited by 211
Cholinergic input to dopaminergic neurons in the substantia nigra: A double immunocytochemical study
Bolam, J. P., Francis, C. M., & Henderson, Z. (1991) · Neuroscience · doi:10.1016/0306-4522(91)90343-m · Cited by 211
Cholinergic modulation of the cortical neuronal network
Lucas-Meunier, E., Fossier, P., Baux, G., & Amar, M. (2003) · Pflügers Archiv - European Journal of Physiology · doi:10.1007/s00424-002-0999-2 · Cited by 210
New atypical antipsychotic medications
Jibson, M. D., & Tandon, R. (1998) · Journal of Psychiatric Research · doi:10.1016/s0022-3956(98)00023-5 · Cited by 208
Self-citationDecreased muscarinic1 receptors in the dorsolateral prefrontal cortex of subjects with schizophrenia
Dean, B., McLeod, M., Keriakous, D., McKenzie, J., & Scarr, E. (2002) · Molecular Psychiatry · doi:10.1038/sj.mp.4001199 · Cited by 207
Self-citationBymaster, F. P., McKinzie, D. L., Felder, C. C., & Wess, J. (2003) · Neurochemical Research · doi:10.1023/a:1022844517200 · Cited by 203
Self-citationBymaster, F. (1999) · Schizophrenia Research · doi:10.1016/s0920-9964(98)00146-7 · Cited by 200
Self-citationTrihexyphenidyl (Artane) abuse in schizophrenic patients
Zemishlany, Z., Aizenberg, D., Weiner, Z., & Weizman, A. (1996) · International Clinical Psychopharmacology · doi:10.1097/00004850-199609000-00007 · Cited by 198
Yeomans, J. (1995) · Neuropsychopharmacology · doi:10.1016/0893-133x(94)00054-4 · Cited by 198
Tandon, R. (1992) · Archives of General Psychiatry · doi:10.1001/archpsyc.1992.01820030017003 · Cited by 193
Tzavara, E. T., Bymaster, F. P., Davis, R. J., Wade, M. R., Perry, K. W., Wess, J., McKinzie, D. L., Felder, C., & Nomikos, G. G. (2004) · The FASEB Journal · doi:10.1096/fj.04-1575fje · Cited by 191
Self-citationClozapine is a potent and selective muscarinic M4 receptor agonist
Zorn, S. H., Jones, S. B., Ward, K. M., & Liston, D. R. (1994) · European Journal of Pharmacology: Molecular Pharmacology · doi:10.1016/0922-4106(94)90047-7 · Cited by 191
Toru, M., Watanabe, S., Shibuya, H., Nishikawa, T., Noda, K., Mitsushio, H., Ichikawa, H., Kurumaji, A., Takashima, M., Mataga, N., et al. (1988) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.1988.tb06312.x · Cited by 191
Friedman, J. (2004) · Psychopharmacology · doi:10.1007/s00213-004-1794-x · Cited by 184
Burstein, E. S., Ma, J., Wong, S., Gao, Y., Pham, E., Knapp, A. E., Nash, N. R., Olsson, R., Davis, R. E., Hacksell, U., et al. (2005) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.105.092155 · Cited by 184
Molecular basis of muscarinic receptor function
Wess, J. (1993) · Trends in Pharmacological Sciences · doi:10.1016/0165-6147(93)90049-p · Cited by 182
Molecular cloning and expression of a fifth muscarinic acetylcholine receptor
Liao, C. F., Themmen, A. P., Joho, R., Barberis, C., Birnbaumer, M., & Birnbaumer, L. (1989) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)83237-9 · Cited by 180
Sugita, S., Uchimura, N., Jiang, Z. G., & North, R. A. (1991) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.88.6.2608 · Cited by 171
Wu, M., Shanabrough, M., Leranth, C., & Alreja, M. (2000) · The Journal of Neuroscience · doi:10.1523/jneurosci.20-10-03900.2000 · Cited by 171
Friedman, J. I., Adler, D. N., Howanitz, E., Harvey, P. D., Brenner, G., Temporini, H., White, L., & Parrella, M. (2002) · Biological Psychiatry · doi:10.1016/s0006-3223(01)01342-7 · Cited by 169
Bymaster, F. P., Carter, P. A., Yamada, M., Gomeza, J., Wess, J., Hamilton, S. E., Nathanson, N. M., McKinzie, D. L., & Felder, C. C. (2003) · European Journal of Neuroscience · doi:10.1046/j.1460-9568.2003.02588.x · Cited by 167
Self-citationSynaptic Integration Mediated by Striatal Cholinergic Interneurons in Basal Ganglia Function
Kaneko, S., Hikida, T., Watanabe, D., Ichinose, H., Nagatsu, T., Kreitman, R. J., Pastan, I., & Nakanishi, S. (2000) · Science · doi:10.1126/science.289.5479.633 · Cited by 166
Katerina, Z., Andrew, K., Filomena, M., & Xu-Feng, H. (2004) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300367 · Cited by 166
Xanomeline and the Antipsychotic Potential of Muscarinic Receptor Subtype Selective Agonists
Mirza, N. R., Peters, D., & Sparks, R. G. (2003) · CNS Drug Reviews · doi:10.1111/j.1527-3458.2003.tb00247.x · Cited by 165
Shannon, H. E., Rasmussen, K., Bymaster, F. P., Hart, J. C., Peters, S. C., Swedberg, M. D. B., Jeppesen, L., Sheardown, M. J., Sauerberg, P., & Fink-Jensen, A. (2000) · Schizophrenia Research · doi:10.1016/s0920-9964(99)00138-3 · Cited by 165
Self-citationMuscarinic and Nicotinic Cholinergic Mechanisms in the Mesostriatal Dopamine Systems
Zhou, F.-M., Wilson, C. J., & Dani, J. A. (2003) · The Neuroscientist · doi:10.1177/1073858402239588 · Cited by 163
Muscarinic and nicotinic receptors synergistically modulate working memory and attention in humans
Ellis, J. R., Ellis, K. A., Bartholomeusz, C. F., Harrison, B. J., Wesnes, K. A., Erskine, F. F., Vitetta, L., & Nathan, P. J. (2005) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145705005407 · Cited by 155
Abnormal Rapid Eye Movement Latencies in Schizophrenia
Zarcone, V. P. (1987) · Archives of General Psychiatry · doi:10.1001/archpsyc.1987.01800130047007 · Cited by 153
Cortical Cholinergic Transmission and Cortical Information Processing in Schizophrenia
Sarter, M. (2005) · Schizophrenia Bulletin · doi:10.1093/schbul/sbi006 · Cited by 153
Dean, B., Crook, J. M., Opeskin, K., Hill, C., Keks, N. A., & Copolov, D. (1996) · PubMed · Cited by 149
Self-citationAdverse effects of anticholinergic medication on positive schizophrenic symptoms
Johnstone, E. C., Crow, T. J., Ferrier, I. N., Frith, C., Owens, D. G. C., Bourne, R. C., & Gamble, S. J. (1983) · Psychological Medicine · doi:10.1017/s0033291700047942 · Cited by 148
Augmented Prefrontal Acetylcholine Release during Challenged Attentional Performance
Kozak, R., Bruno, J. P., & Sarter, M. (2006) · Cerebral Cortex · doi:10.1093/cercor/bhi079 · Cited by 144
The Muscarinic Receptor Agonist Xanomeline Has an Antipsychotic-Like Profile in the Rat
Stanhope, K. J., Mirza, N. R., Bickerdike, M. J., Bright, J. L., Harrington, N. R., Hesselink, M. B., Kennett, G. A., Lightowler, S., Sheardown, M. J., Syed, R., et al. (2001) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)29291-0 · Cited by 142
Li, Z., Huang, M., Ichikawa, J., Dai, J., & Meltzer, H. Y. (2005) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300768 · Cited by 141
Genetics of Chromosome 15q13-q14 in Schizophrenia
Leonard, S. S., & Freedman, R. (2006) · Biological Psychiatry · doi:10.1016/j.biopsych.2006.03.054 · Cited by 140
Evidence for a deficit in cholinergic interneurons in the striatum in schizophrenia
Holt, D. J., Herman, M. M., Hyde, T. M., Kleinman, J. E., Sinton, C. M., German, D. C., Hersh, L. B., Graybiel, A. M., & Saper, C. B. (1999) · Neuroscience · doi:10.1016/s0306-4522(99)00279-1 · Cited by 137
Lehmann, J. C., & Langer, S. Z. (1982) · Brain Research · doi:10.1016/0006-8993(82)91147-7 · Cited by 136
Lokwan, S. J. A., Overton, P. G., Berry, M. S., & Clark, D. T. (1999) · Neuroscience · doi:10.1016/s0306-4522(98)00748-9 · Cited by 134
Davies, M. A., Compton-Toth, B. A., Hufeisen, S. J., Meltzer, H. Y., & Roth, B. L. (2004) · Psychopharmacology · doi:10.1007/s00213-004-2017-1 · Cited by 128
Dewey, S. L., Smith, G. S., Logan, J., Brodie, J. D., Simkowitz, P., MacGregor, R. R., Fowler, J. S., Volkow, N. D., & Wolf, A. P. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.24.11816 · Cited by 126
Cholinergic aspects of schizophrenia
Tandon, R. (1999) · The British Journal of Psychiatry · doi:10.1192/s0007125000293586 · Cited by 121
Self-citationMuscarinic cholinergic hyperactivity in schizophrenia
Tandon, R., Shipley, J. E., Greden, J. F., Mann, N. A., Eisner, W. H., & Goodson, J. A. (1991) · Schizophrenia Research · doi:10.1016/0920-9964(91)90006-d · Cited by 120
Self-citationMesopontine neurons in schizophrenia
García‐Rill, E., Biedermann, J., Chambers, T. C., Skinner, R. D., Mrak, R. E., Husain, M., & Karson, C. N. (1995) · Neuroscience · doi:10.1016/0306-4522(94)00564-l · Cited by 110
Meltzer, H. Y. (2002) · Psychopharmacology · doi:10.1007/s00213-002-1088-0 · Cited by 109
Studies on the electrogenic action of acetylcholine with Torpedo marmorata electric organ
Popot, J., Sugiyama, H., & Changeux, J. (1976) · Journal of Molecular Biology · doi:10.1016/0022-2836(76)90247-3 · Cited by 108
Altered Hippocampal Muscarinic M4, but Not M1, Receptor Expression from Subjects with Schizophrenia
Scarr, E., Sundram, S., Keriakous, D., & Dean, B. (2007) · Biological Psychiatry · doi:10.1016/j.biopsych.2006.08.050 · Cited by 108
Self-citationDistribution of m2 muscarinic receptors in rat brain using antisera selective for m2 receptors.
Li, M., Yasuda, R. P., Wall, S. J., Wellstein, A., & Wolfe, B. B. (1991) · Molecular Pharmacology · doi:10.1016/s0026-895x(25)12846-0 · Cited by 107
Choline acetyltransferase in schizophrenia
Karson, C. N., Casanova, M. F., Kleinman, J. E., & Griffin, W. S. T. (1993) · American Journal of Psychiatry · doi:10.1176/ajp.150.3.454 · Cited by 106
Gronier, B., & Rasmussen, K. (1998) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0701850 · Cited by 106
Buchanan, R. W., Summerfelt, A. T., Tek, C., & Gold, J. M. (2002) · Schizophrenia Research · doi:10.1016/s0920-9964(01)00387-5 · Cited by 105
Muscarinic Cholinergic Modulation of Prepulse Inhibition of the Acoustic Startle Reflex
Jones, C. K., & Shannon, H. E. (2000) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)39166-9 · Cited by 104
Reduced expression of the muscarinic 1 receptor cortical subtype in schizophrenia
Mancama, D. T., Arranz, M. J., Landau, S., & Kerwin, R. W. (2003) · American Journal of Medical Genetics Part B Neuropsychiatric Genetics · doi:10.1002/ajmg.b.20020 · Cited by 104
Autoantibodies against four kinds of neurotransmitter receptors in psychiatric disorders
Tanaka, S., Matsunaga, H., Kimura, M., Tatsumi, K., Hidaka, Y., Takano, T., Uema, T., Takeda, M., & Amino, N. (2003) · Journal of Neuroimmunology · doi:10.1016/s0165-5728(03)00252-2 · Cited by 100
The binding of [3H]AF-DX 384 is reduced in the caudate-putamen of subjects with schizophrenia
Crook, J. M., Dean, B., Pavey, G., & Copolov, D. (1999) · Life Sciences · doi:10.1016/s0024-3205(99)00114-9 · Cited by 100
Self-citationWall, S. J., Yasuda, R. P., Hory, F., Flagg, S. D., Martin, B. M., Ginns, E. I., & Wolfe, B. B. (1991) · Molecular Pharmacology · doi:10.1016/s0026-895x(25)11072-9 · Cited by 100
Shapiro, M. S., Loose, M. D., Hamilton, S. E., Nathanson, N. M., Gomeza, J., Wess, J., & Hille, B. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.19.10899 · Cited by 99
Sullivan, R. J., Allen, J. S., Otto, C., Tiobech, J., & Nero, K. L. (2000) · The British Journal of Psychiatry · doi:10.1192/bjp.177.2.174 · Cited by 98
Decreased density of muscarinic receptors in the superior temporal gyrusin schizophrenia
Deng, C., & Huang, X. (2005) · Journal of Neuroscience Research · doi:10.1002/jnr.20600 · Cited by 96
Andersen, M. B., Fink‐Jensen, A., Peacock, L., Gerlach, J., Bymaster, F. P., Lundbæk, J. A., & Werge, T. M. (2003) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300151 · Cited by 95
Self-citationMiller, A. D., & Blaha, C. D. (2005) · European Journal of Neuroscience · doi:10.1111/j.1460-9568.2005.04017.x · Cited by 93
Chung, Y., Li, Z., Dai, J., Meltzer, H. Y., & Ichikawa, J. (2004) · Brain Research · doi:10.1016/j.brainres.2004.07.009 · Cited by 93
Muscarinic m4 receptor activation by some atypical antipsychotic drugs
Zeng, X. P., Le, F., & Richelson, E. (1997) · European Journal of Pharmacology · doi:10.1016/s0014-2999(96)00956-9 · Cited by 93
SHARMA, T., REED, C., Aasen, I., & Kumari, V. (2006) · Schizophrenia Research · doi:10.1016/j.schres.2006.03.037 · Cited by 84
Jones, C. K., Eberle, E. L., Shaw, D. B., McKinzie, D. L., & Shannon, H. E. (2005) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.104.075887 · Cited by 84
Cholinergic Inhibition of Ventral Midbrain Dopamine Neurons
Fiorillo, C. D., & Williams, J. T. (2000) · Journal of Neuroscience · doi:10.1523/jneurosci.20-20-07855.2000 · Cited by 83
Riemann, D. W., Hohagen, F., Krieger, S., Gann, H., Müller, W. E., Olbrich, R., Wark, H.-J., Bohus, M., Löw, H., & Berger, T. (1994) · Journal of Psychiatric Research · doi:10.1016/0022-3956(94)90006-x · Cited by 83
Tual, Ö., Yazici, M. K., Yağcioğlu, A. E. A., & Göüş, A. (2004) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145703004024 · Cited by 83
Holt, D. J., Bachus, S. E., Hyde, T. M., Wittie, M., Herman, M. M., Vangel, M. G., Saper, C. B., & Kleinman, J. E. (2005) · Biological Psychiatry · doi:10.1016/j.biopsych.2005.04.007 · Cited by 82
In Vivo Olanzapine Occupancy of Muscarinic Acetylcholine Receptors in Patients with Schizophrenia
Raedler, T. J. (2000) · Neuropsychopharmacology · doi:10.1016/s0893-133x(99)00162-1 · Cited by 82
Self-citationFlynn, D. D., & Mash, D. C. (1993) · Synapse · doi:10.1002/syn.890140406 · Cited by 82
Gronier, B., Perry, K. W., & Rasmussen, K. (2000) · Psychopharmacology · doi:10.1007/s002130050002 · Cited by 79
Klippel, N. D., Sarre, S., Ebinger, G., & Michotte, Y. M. (1993) · Brain Research · doi:10.1016/0006-8993(93)90642-z · Cited by 78
Muscarinic Acetylcholine Receptor Knockout Mice
Wess, J., Zhang, W., Duttaroy, A., Miyakawa, T., Gomeza, J., Cui, Y., Basile, A. S., Bymaster, F. P., McKinzie, D. L., Felder, C. C., et al. (2004) · Handbook of experimental pharmacology · doi:10.1007/978-3-642-18934-0_3 · Cited by 73
Self-citationShannon, H. E., Hart, J. C., Bymaster, F. P., Calligaro, D. O., DeLapp, N. W., Mitch, C. H., Ward, J. S., Fink‐Jensen, A., Sauerberg, P., Jeppesen, L., et al. (1999) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)34979-1 · Cited by 73
Self-citationHeterogeneity of presynaptic muscarinic receptors involved in modulation of transmitter release
Vizi, E. S., Kobayashi, O., Törőcsik, A., et al. (1989) · Neuroscience · doi:10.1016/0306-4522(89)90048-1 · Cited by 73
Olianas, M. C., Maullu, C., & Onali, P. (1999) · Neuropsychopharmacology · doi:10.1016/s0893-133x(98)00048-7 · Cited by 71
Ichikawa, J., Chung, Y., Li, Z., Dai, J., & Meltzer, H. Y. (2002) · Brain Research · doi:10.1016/s0006-8993(02)03692-2 · Cited by 71
M2 Muscarinic Autoreceptors Modulate Acetylcholine Release in the Medial Pontine Reticular Formation
Baghdoyan, H. A., Lydic, R., & Fleegal, M. A. (1998) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)37743-2 · Cited by 69
Linkage of M5 Muscarinic and α7-Nicotinic Receptor Genes on 15q13 to Schizophrenia
Luca, V. D., Wang, H., Squassina, A., Wong, G., Yeomans, J. S., & Kennedy, J. L. (2004) · Neuropsychobiology · doi:10.1159/000079102 · Cited by 68
Added donepezil for stable schizophrenia: a double-blind, placebo-controlled trial
Freudenreich, O., Herz, L. R., Deckersbach, T., Evins, A. E., Henderson, D. C., Cather, C., & GOFF, D. C. (2005) · Psychopharmacology · doi:10.1007/s00213-005-2235-1 · Cited by 68
The effects of clozapine on neurocognition: an overview.
Goldberg, T. E., & Weinberger, D. R. (1994) · PubMed · Cited by 68
Bymaster, F. P., Shannon, H. E., Rasmussen, K., DeLapp, N. W., Mitch, C. H., Ward, J. S., Calligaro, D. O., Ludvigsen, T. S., Sheardown, M. J., Olesen, P. H., et al. (1998) · European Journal of Pharmacology · doi:10.1016/s0014-2999(98)00487-7 · Cited by 66
Self-citationEffect of anticholinergics on positive and negative symptoms in schizophrenia.
Tandon, R., DeQuardo, J. R., Goodson, J. A., Mann, N. A., & Greden, J. F. (1992) · PubMed · Cited by 65
Self-citationEffects of Rivastigmine on Cognitive Function and Quality of Life in Patients With Schizophrenia
Lenzi, A., Maltinti, E., Poggi, E., Lazzerini, F., & Coli, E. (2003) · Clinical Neuropharmacology · doi:10.1097/00002826-200311000-00011 · Cited by 62
Nahas, Z. H., George, M. S., Horner, M. D., Markowitz, J. S., Li, X., Lorberbaum, J. P., Owens, S. D., McGurk, S. R., DeVane, L., & Risch, S. C. (2003) · Neurocase · doi:10.1076/neur.9.3.274.15563 · Cited by 62
Stryjer, R., Strous, R. D., Bar, F., Werber, E. A., Shaked, G., Buhiri, Y., Kotler, M., Weizman, A., & Rabey, J. M. (2003) · Clinical Neuropharmacology · doi:10.1097/00002826-200301000-00004 · Cited by 57
Borda, T. G., Rivera, R. P., Joensen, L., Gomez, R. M., & Sterin‐Borda, L. (2002) · The Journal of Immunology · doi:10.4049/jimmunol.168.7.3667 · Cited by 56
Liao, D., Hong, C., Chen, H., Chen, Y.-E., Lee, S.-M., Chang, C.-Y., Chen, H., & Tsai, S. (2003) · Neuropsychobiology · doi:10.1159/000072880 · Cited by 56
Perry, K. W., Nisenbaum, L. K., George, C., Shannon, H. E., Felder, C. C., & Bymaster, F. P. (2001) · Biological Psychiatry · doi:10.1016/s0006-3223(00)01017-9 · Cited by 56
Self-citationOlianas, M. C., Maullu, C., & Onali, P. (1997) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0701357 · Cited by 56
Singh, M. M., Kay, S. R., & Opler, L. A. (1987) · Psychological Medicine · doi:10.1017/s0033291700012964 · Cited by 55
Medications and verbal memory impairment in schizophrenia: the role of anticholinergic drugs
Brébion, G., Bressan, R. A., AMADOR, X. F., Malaspina, D., & Gorman, J. M. (2004) · Psychological Medicine · doi:10.1017/s0033291703008900 · Cited by 54
Muscarinic1 and 2 receptor mRNA in the human caudate-putamen: no change in m1 mRNA in schizophrenia
Dean, B., Crook, J. M., Pavey, G., Opeskin, K., & Copolov, D. (2000) · Molecular Psychiatry · doi:10.1038/sj.mp.4000684 · Cited by 54
Self-citationIncreased muscarinic cholinergic receptors in prefrontal cortices of medicated schizophrenics
Watanabe, S., Nishikawa, T., Takashima, M., & Toru, M. (1983) · Life Sciences · doi:10.1016/0024-3205(83)90290-4 · Cited by 53
Zavitsanou, K., Katsifis, A. G., Yu, Y., & Huang, X. (2005) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2005.02.007 · Cited by 53
Clozapine interaction with the M2 and M4 subtypes of muscarinic receptors
Michal, P., Lysı́ková, M., El‐Fakahany, E. E., & Tuček, S. (1999) · European Journal of Pharmacology · doi:10.1016/s0014-2999(99)00341-6 · Cited by 52
Efficacy and Tolerability of Low-Dose Donepezil in Schizophrenia
Erickson, S. K., Schwarzkopf, S. B., Palumbo, D. R., Badgley-Fleeman, J., Smirnow, A. M., & Light, G. A. (2005) · Clinical Neuropharmacology · doi:10.1097/01.wnf.0000173714.61744.e6 · Cited by 50
No change in cortical muscarinic M2, M3 receptors or [35S]GTPγS binding in schizophrenia
Scarr, E., Keriakous, D., Crossland, N., & Dean, B. (2005) · Life Sciences · doi:10.1016/j.lfs.2005.06.038 · Cited by 50
Self-citationLavalaye, J., Booij, J., Linszen, D. H., Reneman, L., & van Royen, E. A. (2001) · Psychopharmacology · doi:10.1007/s002130000679 · Cited by 47
Impact of Treatment Accessibility on Clinical Course of Parasuicidal Patients
Hoffman, R. E. (1993) · Archives of General Psychiatry · doi:10.1001/archpsyc.1993.01820140083010 · Cited by 46
Treatment of Tardive Dyskinesia With Donepezil: A Pilot Study
Caroff, S. N., Campbell, E. C., Havey, J. C., Sullivan, K. A., Mann, S. C., & Gallop, R. (2001) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v62n1004 · Cited by 41
Antibodies against astrocyte M1 and M2 muscarinic cholinoceptor from schizophrenic patients' sera
Borda, T., Gomez, R. M., Berría, M. I., & Sterin‐Borda, L. (2003) · Glia · doi:10.1002/glia.10312 · Cited by 41
Dopamine prevents muscarinic-induced decrease of glutamate release in the auditory cortex
Atzori, M., Kanold, P. O., Pineda, J. C., Flores‐Hernández, J., & Paz, R. (2005) · Neuroscience · doi:10.1016/j.neuroscience.2005.05.005 · Cited by 41
Chapter 40 Antimuscarinic drugs in the treatment of movement disorders
Fahn, S., Burke, R. E., & Stern, Y. (1990) · Progress in brain research · doi:10.1016/s0079-6123(08)60922-x · Cited by 39
Stryjer, R., Strous, R. D., Bar, F., Shaked, G., Shiloh, R., Rozencwaig, S., Grupper, D., Buchman, N., Kotler, M., Rabey, J. M., et al. (2004) · Human Psychopharmacology Clinical and Experimental · doi:10.1002/hup.595 · Cited by 39
Persistent Binding and Functional Antagonism by Xanomeline at the Muscarinic M5 Receptor
Grant, M. K. O., & El‐Fakahany, E. E. (2005) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.105.090134 · Cited by 38
Effects of Rivastigmine on Sustained Attention in Schizophrenia
Aasen, I., Kumari, V., & Sharma, T. (2005) · Journal of Clinical Psychopharmacology · doi:10.1097/01.jcp.0000169267.36797.76 · Cited by 37
Rasmussen, T., Fink‐Jensen, A., Sauerberg, P., Swedberg, M. D. B., Thomsen, C., Sheardown, M. J., Jeppesen, L., Calligaro, D. O., DeLapp, N. W., Whitesitt, C. A., et al. (2001) · Schizophrenia Research · doi:10.1016/s0920-9964(00)00129-8 · Cited by 37
Self-citationDopamine Receptor Excess and Mouse Madness
Snyder, S. H. (2006) · Neuron · doi:10.1016/j.neuron.2006.02.002 · Cited by 36
Reduction Of Clozapine-Induced Hypersalivation By Pirenzepine Is Safe
Schneider, B., Weigmann, H., Hiemke, C., Weber, B., & Fritze, J. (2004) · Pharmacopsychiatry · doi:10.1055/s-2004-815523 · Cited by 34
Mesopontine cholinergic and non-cholinergic neurons in schizophrenia
German, D. C., Manaye, K. F., Wu, D., Hersh, L. B., & Zweig, R. M. (1999) · Neuroscience · doi:10.1016/s0306-4522(99)00305-x · Cited by 30
Raedler, T. J. (2006) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145706006584 · Cited by 29
Self-citationLaplante, F., Nakagawasai, O., Srivastava, L. K., & Quirion, R. (2004) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300640 · Cited by 28
Siris, S. G. (1995) · Cited by 19
Growth hormone responses to pyridostigmine in schizophrenia: Evidence for cholinergic dysfunction
O’Keane, V., Abel, K. M., & Murray, R. M. (1994) · Biological Psychiatry · doi:10.1016/0006-3223(94)90068-x · Cited by 18
Effects of Atypical Antipsychotics on Polysomnographic Measures in Schizophrenia
Tandon, R. (1997) · KARGER eBooks · doi:10.1159/000059495 · Cited by 15
Self-citationMechanisms of Action of Medicines for Schizophrenia and Bipolar Illness: Status and Limitations
Scolnick, E. M. (2006) · Biological Psychiatry · doi:10.1016/j.biopsych.2006.02.022 · Cited by 14
Ganzinelli, S., Borda, T. G., & Sterin‐Borda, L. (2005) · Neuropharmacology · doi:10.1016/j.neuropharm.2005.09.013 · Cited by 13
Cited by
Muscarinic acetylcholine receptors: mutant mice provide new insights for drug development
Wess, J., Eglen, R. M., & Gautam, D. (2007) · Nature Reviews Drug Discovery · doi:10.1038/nrd2379 · Cited by 637
Current Concepts and Treatments of Schizophrenia
Stępnicki, P., Kondej, M., & Kaczor, A. A. (2018) · Molecules · doi:10.3390/molecules23082087 · Cited by 556
Schizophrenia, “Just the Facts”: What we know in 2008
Tandon, R., Keshavan, M. S., & Nasrallah, H. A. (2008) · Schizophrenia Research · doi:10.1016/j.schres.2008.01.022 · Cited by 409
Self-citationSchizophrenia, “Just the Facts” 5. Treatment and prevention Past, present, and future
Tandon, R., Nasrallah, H. A., & Keshavan, M. S. (2010) · Schizophrenia Research · doi:10.1016/j.schres.2010.05.025 · Cited by 385
Self-citationThe history of the cholinergic hypothesis
Contestabile, A. (2011) · Behavioural Brain Research · doi:10.1016/j.bbr.2009.12.044 · Cited by 374
Metadata
- Authors
- Raedler, T. J., Bymaster, F. P., Tandon, R., Copolov, D., & Dean, B.
- Venue
- Molecular Psychiatry
- Published
- 2006-12-05
- Volume
- 12
- Issue
- 3
- Pages
- 232-246
- ISSN
- 1359-4184 (ISSN-L)
- 1476-5578
- OpenAlex
- W2011128492
- Cited by
- 291
- References
- 191
- FWCI
- 12.07
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.